-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KD1oYUMDws2Ik40xOV2z2j43urQf+ZMJWdpSlnUw8BFo5GkGAn7fKDZyZmB1uYPt kBLlmXUT3IPU6dEGP9DwFg== 0001354457-09-000192.txt : 20090710 0001354457-09-000192.hdr.sgml : 20090710 20090710095234 ACCESSION NUMBER: 0001354457-09-000192 CONFORMED SUBMISSION TYPE: 25-NSE CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20090710 DATE AS OF CHANGE: 20090710 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: XTL BIOPHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001023549 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 25-NSE SEC ACT: 1934 Act SEC FILE NUMBER: 000-51310 BUSINESS ADDRESS: STREET 1: 711 EXECUTIVE BOULEVARD STREET 2: SUITE Q CITY: VALLEY COTTAGE STATE: NY ZIP: 10989 BUSINESS PHONE: 972-8-930-4440 MAIL ADDRESS: STREET 1: 711 EXECUTIVE BOULEVARD STREET 2: SUITE Q CITY: VALLEY COTTAGE STATE: NY ZIP: 10989 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NASDAQ Stock Market LLC CENTRAL INDEX KEY: 0001354457 IRS NUMBER: 521165937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-978-4144 MAIL ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 25-NSE 1 primary_doc.xml X0203 0001354457 NASDAQ Stock Market LLC 0001023549 XTL BIOPHARMACEUTICALS LTD 000-51310
711 Executive Boulevard, Suite Q New York NY NEW YORK 10989
845-267-0707 American Depositary Receipts 17 CFR 240.12d2-2(b) Amy Horton Associate General Counsel 2009-07-10 EX-99.25 2 xtlbdelistreason.txt Delisting Determination,The Nasdaq Stock Market, LLC, July 10, 2009, XTL Biopharmaceuticals Ltd. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of XTL Biopharmaceuticals Ltd. (the Company), effective at the opening of the trading session on July 20, 2009. Based on a review of the information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rules 5100 and 5550(b)(1). The Company was notified of the Staffs determination on January 27, 2009. The Company requested a review of the Staffs determination before the Listing Qualifications Hearings Panel. Upon review of the information provided by the Company, the Panel determined that the Company did not qualify for inclusion on the Exchange based on its failure to comply with the following Listing Rules: 5100 and 5550(b)(1). The Company was notified of the Panels decision on April 15, 2009 and trading in the Companys securities was suspended on April 17, 2009. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on June 1, 2009. -----END PRIVACY-ENHANCED MESSAGE-----